nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—UGT1A1—Estradiol—osteoporosis	0.0508	0.113	CbGbCtD
Pazopanib—SLCO1B1—Conjugated Estrogens—osteoporosis	0.04	0.0895	CbGbCtD
Pazopanib—SLCO1B1—Estradiol—osteoporosis	0.0351	0.0786	CbGbCtD
Pazopanib—ABCG2—Conjugated Estrogens—osteoporosis	0.0318	0.0711	CbGbCtD
Pazopanib—ABCG2—Estradiol—osteoporosis	0.0279	0.0624	CbGbCtD
Pazopanib—CYP1A2—Estropipate—osteoporosis	0.0277	0.062	CbGbCtD
Pazopanib—CYP2C8—Raloxifene—osteoporosis	0.0239	0.0534	CbGbCtD
Pazopanib—CYP2C8—Ethinyl Estradiol—osteoporosis	0.0231	0.0516	CbGbCtD
Pazopanib—FGFR3—epiphyseal plate—osteoporosis	0.0222	0.252	CbGeAlD
Pazopanib—CYP2C8—Cholecalciferol—osteoporosis	0.0185	0.0412	CbGbCtD
Pazopanib—ABCB1—Ethinyl Estradiol—osteoporosis	0.0156	0.0349	CbGbCtD
Pazopanib—CYP2C8—Estradiol—osteoporosis	0.0149	0.0332	CbGbCtD
Pazopanib—CYP3A4—Estropipate—osteoporosis	0.0145	0.0325	CbGbCtD
Pazopanib—CYP3A4—Calcitriol—osteoporosis	0.0145	0.0325	CbGbCtD
Pazopanib—CYP1A2—Conjugated Estrogens—osteoporosis	0.0131	0.0293	CbGbCtD
Pazopanib—CYP2D6—Cholecalciferol—osteoporosis	0.0118	0.0263	CbGbCtD
Pazopanib—CYP3A4—Ergocalciferol—osteoporosis	0.0116	0.026	CbGbCtD
Pazopanib—CYP1A2—Estradiol—osteoporosis	0.0115	0.0257	CbGbCtD
Pazopanib—ABCB1—Conjugated Estrogens—osteoporosis	0.0115	0.0256	CbGbCtD
Pazopanib—ABCB1—Estradiol—osteoporosis	0.0101	0.0225	CbGbCtD
Pazopanib—CYP3A4—Raloxifene—osteoporosis	0.00969	0.0217	CbGbCtD
Pazopanib—CYP3A4—Ethinyl Estradiol—osteoporosis	0.00936	0.0209	CbGbCtD
Pazopanib—FGFR3—skull—osteoporosis	0.00927	0.106	CbGeAlD
Pazopanib—FGF1—periosteum—osteoporosis	0.00782	0.089	CbGeAlD
Pazopanib—CYP3A4—Cholecalciferol—osteoporosis	0.00748	0.0167	CbGbCtD
Pazopanib—CYP3A4—Conjugated Estrogens—osteoporosis	0.00687	0.0154	CbGbCtD
Pazopanib—FGFR2—skull—osteoporosis	0.00607	0.0691	CbGeAlD
Pazopanib—CYP3A4—Estradiol—osteoporosis	0.00603	0.0135	CbGbCtD
Pazopanib—CSF1R—periosteum—osteoporosis	0.00564	0.0643	CbGeAlD
Pazopanib—TAOK1—uterus—osteoporosis	0.00196	0.0223	CbGeAlD
Pazopanib—SH2B3—uterus—osteoporosis	0.00184	0.021	CbGeAlD
Pazopanib—ITK—bone marrow—osteoporosis	0.00182	0.0208	CbGeAlD
Pazopanib—TAOK1—bone marrow—osteoporosis	0.00166	0.0189	CbGeAlD
Pazopanib—SH2B3—bone marrow—osteoporosis	0.00156	0.0178	CbGeAlD
Pazopanib—BMPR1B—uterus—osteoporosis	0.00153	0.0174	CbGeAlD
Pazopanib—FGFR2—Estradiol—Estropipate—osteoporosis	0.00144	0.336	CbGdCrCtD
Pazopanib—PLK4—bone marrow—osteoporosis	0.00141	0.016	CbGeAlD
Pazopanib—PI4KB—uterus—osteoporosis	0.00136	0.0155	CbGeAlD
Pazopanib—LIMK2—uterus—osteoporosis	0.00134	0.0153	CbGeAlD
Pazopanib—RIOK2—bone marrow—osteoporosis	0.00131	0.0149	CbGeAlD
Pazopanib—FGFR1—uterus—osteoporosis	0.00119	0.0135	CbGeAlD
Pazopanib—PI4KB—bone marrow—osteoporosis	0.00116	0.0132	CbGeAlD
Pazopanib—MAP3K2—uterus—osteoporosis	0.00113	0.0129	CbGeAlD
Pazopanib—FGFR2—Estradiol—Conjugated Estrogens—osteoporosis	0.00109	0.254	CbGdCrCtD
Pazopanib—LCK—uterus—osteoporosis	0.00106	0.0121	CbGeAlD
Pazopanib—FLT4—bone marrow—osteoporosis	0.00102	0.0116	CbGeAlD
Pazopanib—PIP4K2C—bone marrow—osteoporosis	0.00102	0.0116	CbGeAlD
Pazopanib—FGFR2—uterus—osteoporosis	0.00101	0.0115	CbGeAlD
Pazopanib—MAP3K2—bone marrow—osteoporosis	0.000963	0.011	CbGeAlD
Pazopanib—FLT1—uterus—osteoporosis	0.000936	0.0107	CbGeAlD
Pazopanib—FGFR2—Estradiol—Ethinyl Estradiol—osteoporosis	0.000916	0.214	CbGdCrCtD
Pazopanib—LCK—bone marrow—osteoporosis	0.000902	0.0103	CbGeAlD
Pazopanib—STK10—uterus—osteoporosis	0.000886	0.0101	CbGeAlD
Pazopanib—TAOK3—uterus—osteoporosis	0.000882	0.01	CbGeAlD
Pazopanib—PDGFRA—uterus—osteoporosis	0.000877	0.00999	CbGeAlD
Pazopanib—PLK4—Fulvestrant—Estradiol—osteoporosis	0.00084	0.196	CbGdCrCtD
Pazopanib—KDR—uterus—osteoporosis	0.000791	0.00901	CbGeAlD
Pazopanib—CSF1R—uterus—osteoporosis	0.000772	0.00879	CbGeAlD
Pazopanib—STK10—bone marrow—osteoporosis	0.000752	0.00856	CbGeAlD
Pazopanib—TAOK3—bone marrow—osteoporosis	0.000749	0.00853	CbGeAlD
Pazopanib—KIT—uterus—osteoporosis	0.000701	0.00798	CbGeAlD
Pazopanib—PDGFRB—uterus—osteoporosis	0.000685	0.0078	CbGeAlD
Pazopanib—KDR—bone marrow—osteoporosis	0.000671	0.00765	CbGeAlD
Pazopanib—CSF1R—bone marrow—osteoporosis	0.000655	0.00746	CbGeAlD
Pazopanib—KIT—bone marrow—osteoporosis	0.000595	0.00678	CbGeAlD
Pazopanib—PDGFRB—bone marrow—osteoporosis	0.000581	0.00662	CbGeAlD
Pazopanib—ABCG2—uterus—osteoporosis	0.000385	0.00438	CbGeAlD
Pazopanib—ABCG2—bone marrow—osteoporosis	0.000327	0.00372	CbGeAlD
Pazopanib—ABCB1—uterus—osteoporosis	0.00019	0.00216	CbGeAlD
Pazopanib—Arthralgia—Pamidronate—osteoporosis	0.000188	0.000793	CcSEcCtD
Pazopanib—Epistaxis—Estradiol—osteoporosis	0.000188	0.000792	CcSEcCtD
Pazopanib—Abdominal pain—Alendronate—osteoporosis	0.000187	0.000788	CcSEcCtD
Pazopanib—Muscle spasms—Conjugated Estrogens—osteoporosis	0.000187	0.000788	CcSEcCtD
Pazopanib—Shock—Risedronate—osteoporosis	0.000187	0.000787	CcSEcCtD
Pazopanib—Anaemia—Zoledronate—osteoporosis	0.000186	0.000787	CcSEcCtD
Pazopanib—Nervous system disorder—Risedronate—osteoporosis	0.000186	0.000784	CcSEcCtD
Pazopanib—Skin disorder—Risedronate—osteoporosis	0.000184	0.000777	CcSEcCtD
Pazopanib—Gastrointestinal pain—Calcitriol—osteoporosis	0.000184	0.000777	CcSEcCtD
Pazopanib—Abdominal pain—Raloxifene—osteoporosis	0.000184	0.000775	CcSEcCtD
Pazopanib—Vision blurred—Conjugated Estrogens—osteoporosis	0.000183	0.000772	CcSEcCtD
Pazopanib—Abdominal pain—Ibandronate—osteoporosis	0.000182	0.000767	CcSEcCtD
Pazopanib—Syncope—Zoledronate—osteoporosis	0.000181	0.000763	CcSEcCtD
Pazopanib—Leukopenia—Zoledronate—osteoporosis	0.000181	0.000762	CcSEcCtD
Pazopanib—Oedema—Pamidronate—osteoporosis	0.00018	0.00076	CcSEcCtD
Pazopanib—Haemoglobin—Estradiol—osteoporosis	0.00018	0.000757	CcSEcCtD
Pazopanib—Infection—Pamidronate—osteoporosis	0.000179	0.000755	CcSEcCtD
Pazopanib—Haemorrhage—Estradiol—osteoporosis	0.000179	0.000753	CcSEcCtD
Pazopanib—Abdominal pain—Calcitriol—osteoporosis	0.000178	0.000751	CcSEcCtD
Pazopanib—Hypoaesthesia—Estradiol—osteoporosis	0.000178	0.00075	CcSEcCtD
Pazopanib—Shock—Pamidronate—osteoporosis	0.000177	0.000748	CcSEcCtD
Pazopanib—Loss of consciousness—Zoledronate—osteoporosis	0.000177	0.000748	CcSEcCtD
Pazopanib—Nervous system disorder—Pamidronate—osteoporosis	0.000177	0.000746	CcSEcCtD
Pazopanib—Thrombocytopenia—Pamidronate—osteoporosis	0.000177	0.000745	CcSEcCtD
Pazopanib—Urinary tract disorder—Estradiol—osteoporosis	0.000176	0.000744	CcSEcCtD
Pazopanib—Vomiting—Etidronic acid—osteoporosis	0.000176	0.000744	CcSEcCtD
Pazopanib—Cough—Zoledronate—osteoporosis	0.000176	0.000743	CcSEcCtD
Pazopanib—Oedema peripheral—Estradiol—osteoporosis	0.000176	0.000742	CcSEcCtD
Pazopanib—Connective tissue disorder—Estradiol—osteoporosis	0.000176	0.00074	CcSEcCtD
Pazopanib—Urethral disorder—Estradiol—osteoporosis	0.000175	0.000739	CcSEcCtD
Pazopanib—Rash—Etidronic acid—osteoporosis	0.000175	0.000738	CcSEcCtD
Pazopanib—Dermatitis—Etidronic acid—osteoporosis	0.000175	0.000737	CcSEcCtD
Pazopanib—Hyperhidrosis—Pamidronate—osteoporosis	0.000174	0.000735	CcSEcCtD
Pazopanib—Syncope—Conjugated Estrogens—osteoporosis	0.000174	0.000735	CcSEcCtD
Pazopanib—Hypertension—Zoledronate—osteoporosis	0.000174	0.000735	CcSEcCtD
Pazopanib—Headache—Etidronic acid—osteoporosis	0.000174	0.000733	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000173	0.000729	CcSEcCtD
Pazopanib—Asthenia—Estropipate—osteoporosis	0.000172	0.000726	CcSEcCtD
Pazopanib—Anorexia—Pamidronate—osteoporosis	0.000172	0.000725	CcSEcCtD
Pazopanib—Arthralgia—Zoledronate—osteoporosis	0.000172	0.000725	CcSEcCtD
Pazopanib—Chest pain—Zoledronate—osteoporosis	0.000172	0.000725	CcSEcCtD
Pazopanib—Myalgia—Zoledronate—osteoporosis	0.000172	0.000725	CcSEcCtD
Pazopanib—Insomnia—Risedronate—osteoporosis	0.000172	0.000724	CcSEcCtD
Pazopanib—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000171	0.00072	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000171	0.00072	CcSEcCtD
Pazopanib—Paraesthesia—Risedronate—osteoporosis	0.00017	0.000718	CcSEcCtD
Pazopanib—Pruritus—Estropipate—osteoporosis	0.00017	0.000716	CcSEcCtD
Pazopanib—Asthenia—Alendronate—osteoporosis	0.00017	0.000715	CcSEcCtD
Pazopanib—Cough—Conjugated Estrogens—osteoporosis	0.00017	0.000715	CcSEcCtD
Pazopanib—Dyspnoea—Risedronate—osteoporosis	0.000169	0.000713	CcSEcCtD
Pazopanib—Dry mouth—Zoledronate—osteoporosis	0.000168	0.000709	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000168	0.000708	CcSEcCtD
Pazopanib—Fatigue—Ethinyl Estradiol—osteoporosis	0.000168	0.000707	CcSEcCtD
Pazopanib—Pruritus—Alendronate—osteoporosis	0.000167	0.000705	CcSEcCtD
Pazopanib—Dyspepsia—Risedronate—osteoporosis	0.000167	0.000704	CcSEcCtD
Pazopanib—Eye disorder—Estradiol—osteoporosis	0.000167	0.000704	CcSEcCtD
Pazopanib—Cardiac disorder—Estradiol—osteoporosis	0.000166	0.000699	CcSEcCtD
Pazopanib—Flushing—Estradiol—osteoporosis	0.000166	0.000699	CcSEcCtD
Pazopanib—Arthralgia—Conjugated Estrogens—osteoporosis	0.000165	0.000698	CcSEcCtD
Pazopanib—Chest pain—Conjugated Estrogens—osteoporosis	0.000165	0.000698	CcSEcCtD
Pazopanib—Myalgia—Conjugated Estrogens—osteoporosis	0.000165	0.000698	CcSEcCtD
Pazopanib—Asthenia—Ibandronate—osteoporosis	0.000165	0.000696	CcSEcCtD
Pazopanib—Nausea—Etidronic acid—osteoporosis	0.000165	0.000695	CcSEcCtD
Pazopanib—Oedema—Zoledronate—osteoporosis	0.000165	0.000695	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000164	0.000693	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000164	0.000693	CcSEcCtD
Pazopanib—Diarrhoea—Estropipate—osteoporosis	0.000164	0.000693	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Risedronate—osteoporosis	0.000164	0.000691	CcSEcCtD
Pazopanib—Infection—Zoledronate—osteoporosis	0.000164	0.00069	CcSEcCtD
Pazopanib—Fatigue—Risedronate—osteoporosis	0.000163	0.00069	CcSEcCtD
Pazopanib—Insomnia—Pamidronate—osteoporosis	0.000163	0.000688	CcSEcCtD
Pazopanib—Pruritus—Ibandronate—osteoporosis	0.000163	0.000687	CcSEcCtD
Pazopanib—Pain—Risedronate—osteoporosis	0.000162	0.000684	CcSEcCtD
Pazopanib—Angiopathy—Estradiol—osteoporosis	0.000162	0.000684	CcSEcCtD
Pazopanib—Shock—Zoledronate—osteoporosis	0.000162	0.000683	CcSEcCtD
Pazopanib—Paraesthesia—Pamidronate—osteoporosis	0.000162	0.000683	CcSEcCtD
Pazopanib—Diarrhoea—Alendronate—osteoporosis	0.000162	0.000682	CcSEcCtD
Pazopanib—Asthenia—Calcitriol—osteoporosis	0.000162	0.000682	CcSEcCtD
Pazopanib—Nervous system disorder—Zoledronate—osteoporosis	0.000161	0.000681	CcSEcCtD
Pazopanib—Thrombocytopenia—Zoledronate—osteoporosis	0.000161	0.00068	CcSEcCtD
Pazopanib—ABCB1—bone marrow—osteoporosis	0.000161	0.00183	CbGeAlD
Pazopanib—Mediastinal disorder—Estradiol—osteoporosis	0.000161	0.000679	CcSEcCtD
Pazopanib—Dyspnoea—Pamidronate—osteoporosis	0.000161	0.000678	CcSEcCtD
Pazopanib—Chills—Estradiol—osteoporosis	0.00016	0.000676	CcSEcCtD
Pazopanib—Somnolence—Pamidronate—osteoporosis	0.00016	0.000676	CcSEcCtD
Pazopanib—Skin disorder—Zoledronate—osteoporosis	0.00016	0.000675	CcSEcCtD
Pazopanib—Pruritus—Calcitriol—osteoporosis	0.000159	0.000672	CcSEcCtD
Pazopanib—Hyperhidrosis—Zoledronate—osteoporosis	0.000159	0.000671	CcSEcCtD
Pazopanib—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000159	0.000671	CcSEcCtD
Pazopanib—Diarrhoea—Raloxifene—osteoporosis	0.000159	0.000671	CcSEcCtD
Pazopanib—Dyspepsia—Pamidronate—osteoporosis	0.000159	0.000669	CcSEcCtD
Pazopanib—Dizziness—Estropipate—osteoporosis	0.000159	0.000669	CcSEcCtD
Pazopanib—Oedema—Conjugated Estrogens—osteoporosis	0.000159	0.000669	CcSEcCtD
Pazopanib—Alopecia—Estradiol—osteoporosis	0.000158	0.000666	CcSEcCtD
Pazopanib—Infection—Conjugated Estrogens—osteoporosis	0.000158	0.000664	CcSEcCtD
Pazopanib—Diarrhoea—Ibandronate—osteoporosis	0.000157	0.000664	CcSEcCtD
Pazopanib—Anorexia—Zoledronate—osteoporosis	0.000157	0.000662	CcSEcCtD
Pazopanib—Decreased appetite—Pamidronate—osteoporosis	0.000157	0.000661	CcSEcCtD
Pazopanib—Mental disorder—Estradiol—osteoporosis	0.000156	0.00066	CcSEcCtD
Pazopanib—Dizziness—Alendronate—osteoporosis	0.000156	0.000659	CcSEcCtD
Pazopanib—Shock—Conjugated Estrogens—osteoporosis	0.000156	0.000658	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000156	0.000657	CcSEcCtD
Pazopanib—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000155	0.000656	CcSEcCtD
Pazopanib—Erythema—Estradiol—osteoporosis	0.000155	0.000656	CcSEcCtD
Pazopanib—Malnutrition—Estradiol—osteoporosis	0.000155	0.000656	CcSEcCtD
Pazopanib—Fatigue—Pamidronate—osteoporosis	0.000155	0.000656	CcSEcCtD
Pazopanib—Gastrointestinal pain—Risedronate—osteoporosis	0.000155	0.000654	CcSEcCtD
Pazopanib—Pain—Pamidronate—osteoporosis	0.000154	0.00065	CcSEcCtD
Pazopanib—Diarrhoea—Calcitriol—osteoporosis	0.000154	0.00065	CcSEcCtD
Pazopanib—Skin disorder—Conjugated Estrogens—osteoporosis	0.000154	0.00065	CcSEcCtD
Pazopanib—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000154	0.000649	CcSEcCtD
Pazopanib—Dizziness—Raloxifene—osteoporosis	0.000154	0.000648	CcSEcCtD
Pazopanib—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000153	0.000647	CcSEcCtD
Pazopanib—Flatulence—Estradiol—osteoporosis	0.000153	0.000646	CcSEcCtD
Pazopanib—Vomiting—Estropipate—osteoporosis	0.000153	0.000644	CcSEcCtD
Pazopanib—Dysgeusia—Estradiol—osteoporosis	0.000152	0.000642	CcSEcCtD
Pazopanib—Dizziness—Ibandronate—osteoporosis	0.000152	0.000642	CcSEcCtD
Pazopanib—Rash—Estropipate—osteoporosis	0.000151	0.000638	CcSEcCtD
Pazopanib—Dermatitis—Estropipate—osteoporosis	0.000151	0.000638	CcSEcCtD
Pazopanib—Anorexia—Conjugated Estrogens—osteoporosis	0.000151	0.000638	CcSEcCtD
Pazopanib—Headache—Estropipate—osteoporosis	0.00015	0.000634	CcSEcCtD
Pazopanib—Vomiting—Alendronate—osteoporosis	0.00015	0.000634	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.00015	0.000633	CcSEcCtD
Pazopanib—Abdominal pain—Risedronate—osteoporosis	0.00015	0.000632	CcSEcCtD
Pazopanib—Muscle spasms—Estradiol—osteoporosis	0.000149	0.000631	CcSEcCtD
Pazopanib—Rash—Alendronate—osteoporosis	0.000149	0.000629	CcSEcCtD
Pazopanib—Insomnia—Zoledronate—osteoporosis	0.000149	0.000628	CcSEcCtD
Pazopanib—Dermatitis—Alendronate—osteoporosis	0.000149	0.000628	CcSEcCtD
Pazopanib—Headache—Alendronate—osteoporosis	0.000148	0.000625	CcSEcCtD
Pazopanib—Paraesthesia—Zoledronate—osteoporosis	0.000148	0.000624	CcSEcCtD
Pazopanib—Vomiting—Raloxifene—osteoporosis	0.000148	0.000623	CcSEcCtD
Pazopanib—Gastrointestinal pain—Pamidronate—osteoporosis	0.000147	0.000622	CcSEcCtD
Pazopanib—Dyspnoea—Zoledronate—osteoporosis	0.000147	0.000619	CcSEcCtD
Pazopanib—Rash—Raloxifene—osteoporosis	0.000147	0.000618	CcSEcCtD
Pazopanib—Dermatitis—Raloxifene—osteoporosis	0.000146	0.000618	CcSEcCtD
Pazopanib—Somnolence—Zoledronate—osteoporosis	0.000146	0.000617	CcSEcCtD
Pazopanib—Vomiting—Ibandronate—osteoporosis	0.000146	0.000617	CcSEcCtD
Pazopanib—Headache—Raloxifene—osteoporosis	0.000146	0.000614	CcSEcCtD
Pazopanib—Rash—Ibandronate—osteoporosis	0.000145	0.000612	CcSEcCtD
Pazopanib—Dermatitis—Ibandronate—osteoporosis	0.000145	0.000611	CcSEcCtD
Pazopanib—Dyspepsia—Zoledronate—osteoporosis	0.000145	0.000611	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000144	0.000609	CcSEcCtD
Pazopanib—Headache—Ibandronate—osteoporosis	0.000144	0.000608	CcSEcCtD
Pazopanib—Insomnia—Conjugated Estrogens—osteoporosis	0.000143	0.000605	CcSEcCtD
Pazopanib—Vomiting—Calcitriol—osteoporosis	0.000143	0.000604	CcSEcCtD
Pazopanib—Decreased appetite—Zoledronate—osteoporosis	0.000143	0.000604	CcSEcCtD
Pazopanib—Nausea—Estropipate—osteoporosis	0.000143	0.000601	CcSEcCtD
Pazopanib—Abdominal pain—Pamidronate—osteoporosis	0.000143	0.000601	CcSEcCtD
Pazopanib—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000142	0.000601	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000142	0.0006	CcSEcCtD
Pazopanib—Rash—Calcitriol—osteoporosis	0.000142	0.000599	CcSEcCtD
Pazopanib—Fatigue—Zoledronate—osteoporosis	0.000142	0.000599	CcSEcCtD
Pazopanib—Dermatitis—Calcitriol—osteoporosis	0.000142	0.000599	CcSEcCtD
Pazopanib—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000141	0.000596	CcSEcCtD
Pazopanib—Headache—Calcitriol—osteoporosis	0.000141	0.000595	CcSEcCtD
Pazopanib—Somnolence—Conjugated Estrogens—osteoporosis	0.000141	0.000595	CcSEcCtD
Pazopanib—Pain—Zoledronate—osteoporosis	0.000141	0.000594	CcSEcCtD
Pazopanib—Nausea—Alendronate—osteoporosis	0.00014	0.000592	CcSEcCtD
Pazopanib—Dyspepsia—Conjugated Estrogens—osteoporosis	0.00014	0.000589	CcSEcCtD
Pazopanib—Asthenia—Ethinyl Estradiol—osteoporosis	0.00014	0.000589	CcSEcCtD
Pazopanib—Syncope—Estradiol—osteoporosis	0.000139	0.000588	CcSEcCtD
Pazopanib—Nausea—Raloxifene—osteoporosis	0.000138	0.000582	CcSEcCtD
Pazopanib—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000138	0.000581	CcSEcCtD
Pazopanib—Pruritus—Ethinyl Estradiol—osteoporosis	0.000138	0.00058	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000137	0.000577	CcSEcCtD
Pazopanib—Fatigue—Conjugated Estrogens—osteoporosis	0.000137	0.000577	CcSEcCtD
Pazopanib—Nausea—Ibandronate—osteoporosis	0.000137	0.000577	CcSEcCtD
Pazopanib—Loss of consciousness—Estradiol—osteoporosis	0.000137	0.000576	CcSEcCtD
Pazopanib—Asthenia—Risedronate—osteoporosis	0.000136	0.000574	CcSEcCtD
Pazopanib—Cough—Estradiol—osteoporosis	0.000136	0.000572	CcSEcCtD
Pazopanib—Pain—Conjugated Estrogens—osteoporosis	0.000136	0.000572	CcSEcCtD
Pazopanib—Gastrointestinal pain—Zoledronate—osteoporosis	0.000135	0.000568	CcSEcCtD
Pazopanib—Hypertension—Estradiol—osteoporosis	0.000134	0.000566	CcSEcCtD
Pazopanib—Pruritus—Risedronate—osteoporosis	0.000134	0.000566	CcSEcCtD
Pazopanib—Nausea—Calcitriol—osteoporosis	0.000134	0.000564	CcSEcCtD
Pazopanib—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000133	0.000561	CcSEcCtD
Pazopanib—Chest pain—Estradiol—osteoporosis	0.000132	0.000558	CcSEcCtD
Pazopanib—Arthralgia—Estradiol—osteoporosis	0.000132	0.000558	CcSEcCtD
Pazopanib—Myalgia—Estradiol—osteoporosis	0.000132	0.000558	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000131	0.000555	CcSEcCtD
Pazopanib—Abdominal pain—Zoledronate—osteoporosis	0.00013	0.000549	CcSEcCtD
Pazopanib—Diarrhoea—Risedronate—osteoporosis	0.00013	0.000547	CcSEcCtD
Pazopanib—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.00013	0.000547	CcSEcCtD
Pazopanib—Dry mouth—Estradiol—osteoporosis	0.000129	0.000546	CcSEcCtD
Pazopanib—Asthenia—Pamidronate—osteoporosis	0.000129	0.000546	CcSEcCtD
Pazopanib—Dizziness—Ethinyl Estradiol—osteoporosis	0.000129	0.000543	CcSEcCtD
Pazopanib—Pruritus—Pamidronate—osteoporosis	0.000128	0.000538	CcSEcCtD
Pazopanib—Oedema—Estradiol—osteoporosis	0.000127	0.000535	CcSEcCtD
Pazopanib—Infection—Estradiol—osteoporosis	0.000126	0.000532	CcSEcCtD
Pazopanib—Dizziness—Risedronate—osteoporosis	0.000125	0.000529	CcSEcCtD
Pazopanib—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000125	0.000529	CcSEcCtD
Pazopanib—Shock—Estradiol—osteoporosis	0.000125	0.000527	CcSEcCtD
Pazopanib—Nervous system disorder—Estradiol—osteoporosis	0.000124	0.000525	CcSEcCtD
Pazopanib—Vomiting—Ethinyl Estradiol—osteoporosis	0.000124	0.000522	CcSEcCtD
Pazopanib—Diarrhoea—Pamidronate—osteoporosis	0.000123	0.00052	CcSEcCtD
Pazopanib—Skin disorder—Estradiol—osteoporosis	0.000123	0.00052	CcSEcCtD
Pazopanib—Hyperhidrosis—Estradiol—osteoporosis	0.000123	0.000517	CcSEcCtD
Pazopanib—Rash—Ethinyl Estradiol—osteoporosis	0.000123	0.000517	CcSEcCtD
Pazopanib—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000123	0.000517	CcSEcCtD
Pazopanib—Headache—Ethinyl Estradiol—osteoporosis	0.000122	0.000514	CcSEcCtD
Pazopanib—Vomiting—Risedronate—osteoporosis	0.000121	0.000509	CcSEcCtD
Pazopanib—Rash—Risedronate—osteoporosis	0.00012	0.000504	CcSEcCtD
Pazopanib—Dermatitis—Risedronate—osteoporosis	0.000119	0.000504	CcSEcCtD
Pazopanib—Dizziness—Pamidronate—osteoporosis	0.000119	0.000503	CcSEcCtD
Pazopanib—Headache—Risedronate—osteoporosis	0.000119	0.000501	CcSEcCtD
Pazopanib—Asthenia—Zoledronate—osteoporosis	0.000118	0.000498	CcSEcCtD
Pazopanib—Pruritus—Zoledronate—osteoporosis	0.000117	0.000491	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000116	0.000488	CcSEcCtD
Pazopanib—Nausea—Ethinyl Estradiol—osteoporosis	0.000116	0.000487	CcSEcCtD
Pazopanib—Insomnia—Estradiol—osteoporosis	0.000115	0.000484	CcSEcCtD
Pazopanib—Vomiting—Pamidronate—osteoporosis	0.000115	0.000483	CcSEcCtD
Pazopanib—Paraesthesia—Estradiol—osteoporosis	0.000114	0.000481	CcSEcCtD
Pazopanib—Asthenia—Conjugated Estrogens—osteoporosis	0.000114	0.00048	CcSEcCtD
Pazopanib—Rash—Pamidronate—osteoporosis	0.000114	0.000479	CcSEcCtD
Pazopanib—Dermatitis—Pamidronate—osteoporosis	0.000114	0.000479	CcSEcCtD
Pazopanib—Dyspnoea—Estradiol—osteoporosis	0.000113	0.000477	CcSEcCtD
Pazopanib—Headache—Pamidronate—osteoporosis	0.000113	0.000476	CcSEcCtD
Pazopanib—Somnolence—Estradiol—osteoporosis	0.000113	0.000476	CcSEcCtD
Pazopanib—Diarrhoea—Zoledronate—osteoporosis	0.000113	0.000475	CcSEcCtD
Pazopanib—Nausea—Risedronate—osteoporosis	0.000113	0.000475	CcSEcCtD
Pazopanib—Pruritus—Conjugated Estrogens—osteoporosis	0.000112	0.000473	CcSEcCtD
Pazopanib—Dyspepsia—Estradiol—osteoporosis	0.000112	0.000471	CcSEcCtD
Pazopanib—Decreased appetite—Estradiol—osteoporosis	0.00011	0.000465	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Estradiol—osteoporosis	0.00011	0.000462	CcSEcCtD
Pazopanib—Fatigue—Estradiol—osteoporosis	0.000109	0.000461	CcSEcCtD
Pazopanib—Dizziness—Zoledronate—osteoporosis	0.000109	0.000459	CcSEcCtD
Pazopanib—Pain—Estradiol—osteoporosis	0.000109	0.000458	CcSEcCtD
Pazopanib—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000108	0.000458	CcSEcCtD
Pazopanib—Nausea—Pamidronate—osteoporosis	0.000107	0.000452	CcSEcCtD
Pazopanib—Dizziness—Conjugated Estrogens—osteoporosis	0.000105	0.000442	CcSEcCtD
Pazopanib—Vomiting—Zoledronate—osteoporosis	0.000105	0.000442	CcSEcCtD
Pazopanib—Rash—Zoledronate—osteoporosis	0.000104	0.000438	CcSEcCtD
Pazopanib—Gastrointestinal pain—Estradiol—osteoporosis	0.000104	0.000438	CcSEcCtD
Pazopanib—Dermatitis—Zoledronate—osteoporosis	0.000104	0.000438	CcSEcCtD
Pazopanib—Headache—Zoledronate—osteoporosis	0.000103	0.000435	CcSEcCtD
Pazopanib—Vomiting—Conjugated Estrogens—osteoporosis	0.000101	0.000425	CcSEcCtD
Pazopanib—Abdominal pain—Estradiol—osteoporosis	0.0001	0.000423	CcSEcCtD
Pazopanib—Rash—Conjugated Estrogens—osteoporosis	0.0001	0.000422	CcSEcCtD
Pazopanib—Dermatitis—Conjugated Estrogens—osteoporosis	9.99e-05	0.000421	CcSEcCtD
Pazopanib—Headache—Conjugated Estrogens—osteoporosis	9.93e-05	0.000419	CcSEcCtD
Pazopanib—Nausea—Zoledronate—osteoporosis	9.78e-05	0.000413	CcSEcCtD
Pazopanib—Nausea—Conjugated Estrogens—osteoporosis	9.42e-05	0.000397	CcSEcCtD
Pazopanib—Asthenia—Estradiol—osteoporosis	9.1e-05	0.000384	CcSEcCtD
Pazopanib—Pruritus—Estradiol—osteoporosis	8.98e-05	0.000379	CcSEcCtD
Pazopanib—Diarrhoea—Estradiol—osteoporosis	8.68e-05	0.000366	CcSEcCtD
Pazopanib—Dizziness—Estradiol—osteoporosis	8.39e-05	0.000354	CcSEcCtD
Pazopanib—Vomiting—Estradiol—osteoporosis	8.07e-05	0.00034	CcSEcCtD
Pazopanib—Rash—Estradiol—osteoporosis	8e-05	0.000338	CcSEcCtD
Pazopanib—Dermatitis—Estradiol—osteoporosis	7.99e-05	0.000337	CcSEcCtD
Pazopanib—Headache—Estradiol—osteoporosis	7.95e-05	0.000335	CcSEcCtD
Pazopanib—Nausea—Estradiol—osteoporosis	7.54e-05	0.000318	CcSEcCtD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	6.84e-06	3.06e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IRS1—osteoporosis	6.83e-06	3.06e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—IGF1—osteoporosis	6.81e-06	3.05e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—ADCY5—osteoporosis	6.79e-06	3.04e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—RAP1A—osteoporosis	6.78e-06	3.03e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—GPX1—osteoporosis	6.77e-06	3.03e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—IRS1—osteoporosis	6.76e-06	3.03e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PNP—osteoporosis	6.75e-06	3.02e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ATIC—osteoporosis	6.75e-06	3.02e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL6R—osteoporosis	6.74e-06	3.01e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—IRS2—osteoporosis	6.73e-06	3.01e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IL6R—osteoporosis	6.73e-06	3.01e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—SPP1—osteoporosis	6.68e-06	2.99e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—SPP1—osteoporosis	6.66e-06	2.98e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ACP5—osteoporosis	6.66e-06	2.98e-05	CbGpPWpGaD
Pazopanib—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	6.65e-06	2.98e-05	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	6.64e-06	2.97e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IGF1—osteoporosis	6.63e-06	2.97e-05	CbGpPWpGaD
Pazopanib—FGFR1—Developmental Biology—IL6—osteoporosis	6.63e-06	2.97e-05	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—IL6—osteoporosis	6.6e-06	2.95e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—POMC—osteoporosis	6.58e-06	2.94e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—TPI1—osteoporosis	6.57e-06	2.94e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—MYC—osteoporosis	6.54e-06	2.92e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—MTHFR—osteoporosis	6.54e-06	2.92e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—TGFB1—osteoporosis	6.52e-06	2.92e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IRS2—osteoporosis	6.48e-06	2.9e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IL6R—osteoporosis	6.42e-06	2.87e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IRS2—osteoporosis	6.36e-06	2.85e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—IL6R—osteoporosis	6.35e-06	2.84e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KL—osteoporosis	6.35e-06	2.84e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—LEP—osteoporosis	6.34e-06	2.84e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IGF1—osteoporosis	6.33e-06	2.83e-05	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—IL6—osteoporosis	6.28e-06	2.81e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—IL1B—osteoporosis	6.25e-06	2.8e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—MTHFR—osteoporosis	6.25e-06	2.8e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—ADCY5—osteoporosis	6.23e-06	2.79e-05	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—TGFB1—osteoporosis	6.23e-06	2.79e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—LEP—osteoporosis	6.23e-06	2.79e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—IRS2—osteoporosis	6.22e-06	2.78e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—GPX1—osteoporosis	6.21e-06	2.78e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—ADCY5—osteoporosis	6.2e-06	2.77e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—TPI1—osteoporosis	6.19e-06	2.77e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—P4HB—osteoporosis	6.17e-06	2.76e-05	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—IL6—osteoporosis	6.17e-06	2.76e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—IDH2—osteoporosis	6.17e-06	2.76e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—IL1B—osteoporosis	6.14e-06	2.75e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—ADCY5—osteoporosis	6.07e-06	2.72e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GAPDH—osteoporosis	6.06e-06	2.71e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—ESR1—osteoporosis	6.05e-06	2.71e-05	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—IL6—osteoporosis	6.04e-06	2.7e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IRS2—osteoporosis	6.04e-06	2.7e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IRS2—osteoporosis	6.02e-06	2.69e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—SPP1—osteoporosis	6e-06	2.68e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—MYC—osteoporosis	5.99e-06	2.68e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—TGFB1—osteoporosis	5.98e-06	2.67e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—ESR1—osteoporosis	5.94e-06	2.66e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—osteoporosis	5.91e-06	2.64e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—LEP—osteoporosis	5.91e-06	2.64e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—RAP1A—osteoporosis	5.9e-06	2.64e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—LEP—osteoporosis	5.89e-06	2.64e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—IRS1—osteoporosis	5.88e-06	2.63e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—SPP1—osteoporosis	5.87e-06	2.63e-05	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—IL6—osteoporosis	5.86e-06	2.62e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—IL6—osteoporosis	5.84e-06	2.61e-05	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—IL6—osteoporosis	5.83e-06	2.61e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—IL1B—osteoporosis	5.83e-06	2.61e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—P4HB—osteoporosis	5.82e-06	2.6e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—IL1B—osteoporosis	5.81e-06	2.6e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP27A1—osteoporosis	5.8e-06	2.59e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—ADCY5—osteoporosis	5.77e-06	2.58e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—GPX1—osteoporosis	5.75e-06	2.57e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CA2—osteoporosis	5.74e-06	2.57e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—OXCT1—osteoporosis	5.74e-06	2.57e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—MTHFR—osteoporosis	5.73e-06	2.56e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GAPDH—osteoporosis	5.71e-06	2.56e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IRS1—osteoporosis	5.66e-06	2.53e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—ESR1—osteoporosis	5.64e-06	2.52e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ACP5—osteoporosis	5.64e-06	2.52e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—ESR1—osteoporosis	5.63e-06	2.52e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—MGLL—osteoporosis	5.6e-06	2.5e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	5.57e-06	2.49e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—RAP1A—osteoporosis	5.56e-06	2.49e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IRS1—osteoporosis	5.55e-06	2.49e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL6R—osteoporosis	5.52e-06	2.47e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ENO1—osteoporosis	5.48e-06	2.45e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—POMC—osteoporosis	5.45e-06	2.44e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—MYC—osteoporosis	5.43e-06	2.43e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—IRS1—osteoporosis	5.43e-06	2.43e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IRS2—osteoporosis	5.43e-06	2.43e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—TGFB1—osteoporosis	5.42e-06	2.42e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PSMA2—osteoporosis	5.4e-06	2.42e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PSMA5—osteoporosis	5.4e-06	2.42e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—POMC—osteoporosis	5.35e-06	2.39e-05	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—IL6—osteoporosis	5.32e-06	2.38e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL6R—osteoporosis	5.31e-06	2.38e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IRS2—osteoporosis	5.31e-06	2.38e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—LEP—osteoporosis	5.31e-06	2.38e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—MTHFR—osteoporosis	5.3e-06	2.37e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IRS1—osteoporosis	5.27e-06	2.36e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—IL6—osteoporosis	5.26e-06	2.36e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IRS1—osteoporosis	5.26e-06	2.35e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—TPI1—osteoporosis	5.24e-06	2.35e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IGF1—osteoporosis	5.24e-06	2.34e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL1B—osteoporosis	5.24e-06	2.34e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL6R—osteoporosis	5.22e-06	2.33e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—LEP—osteoporosis	5.2e-06	2.33e-05	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—IL6—osteoporosis	5.15e-06	2.31e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IGF1—osteoporosis	5.14e-06	2.3e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL1B—osteoporosis	5.13e-06	2.29e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—IL6R—osteoporosis	5.1e-06	2.28e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—POMC—osteoporosis	5.08e-06	2.27e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—ESR1—osteoporosis	5.07e-06	2.27e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—POMC—osteoporosis	5.06e-06	2.27e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—POMC—osteoporosis	5e-06	2.24e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ADCY5—osteoporosis	4.98e-06	2.23e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—ESR1—osteoporosis	4.96e-06	2.22e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL6R—osteoporosis	4.95e-06	2.22e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL6R—osteoporosis	4.94e-06	2.21e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—P4HB—osteoporosis	4.93e-06	2.21e-05	CbGpPWpGaD
Pazopanib—FGFR3—Disease—IL6—osteoporosis	4.91e-06	2.2e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IGF1—osteoporosis	4.88e-06	2.18e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IGF1—osteoporosis	4.87e-06	2.18e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GAPDH—osteoporosis	4.84e-06	2.17e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—SPP1—osteoporosis	4.81e-06	2.15e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ENO1—osteoporosis	4.77e-06	2.14e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—IDH2—osteoporosis	4.76e-06	2.13e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IRS1—osteoporosis	4.74e-06	2.12e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—RAP1A—osteoporosis	4.71e-06	2.11e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PSMA5—osteoporosis	4.7e-06	2.1e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PSMA2—osteoporosis	4.7e-06	2.1e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IRS1—osteoporosis	4.64e-06	2.07e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—POMC—osteoporosis	4.58e-06	2.05e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—MYC—osteoporosis	4.58e-06	2.05e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—TGFB1—osteoporosis	4.57e-06	2.04e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—POMC—osteoporosis	4.56e-06	2.04e-05	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—IL6—osteoporosis	4.5e-06	2.02e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ENO1—osteoporosis	4.5e-06	2.01e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—MYC—osteoporosis	4.5e-06	2.01e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—TGFB1—osteoporosis	4.48e-06	2.01e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP27A1—osteoporosis	4.47e-06	2e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—POMC—osteoporosis	4.47e-06	2e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL6R—osteoporosis	4.45e-06	1.99e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PSMA2—osteoporosis	4.43e-06	1.98e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PSMA5—osteoporosis	4.43e-06	1.98e-05	CbGpPWpGaD
Pazopanib—FGF1—Immune System—IL6—osteoporosis	4.42e-06	1.98e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—MYC—osteoporosis	4.41e-06	1.98e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—TGFB1—osteoporosis	4.4e-06	1.97e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IGF1—osteoporosis	4.39e-06	1.96e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CYP19A1—osteoporosis	4.38e-06	1.96e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL6R—osteoporosis	4.36e-06	1.95e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IRS2—osteoporosis	4.35e-06	1.95e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ACP5—osteoporosis	4.35e-06	1.95e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IGF1—osteoporosis	4.3e-06	1.92e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—LEP—osteoporosis	4.26e-06	1.91e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—POMC—osteoporosis	4.24e-06	1.9e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—IL6—osteoporosis	4.22e-06	1.89e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL1B—osteoporosis	4.2e-06	1.88e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—MYC—osteoporosis	4.19e-06	1.87e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—TGFB1—osteoporosis	4.18e-06	1.87e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—MYC—osteoporosis	4.18e-06	1.87e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—TGFB1—osteoporosis	4.17e-06	1.87e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	4.11e-06	1.84e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—MYC—osteoporosis	4.09e-06	1.83e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—IL6—osteoporosis	4.08e-06	1.83e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TGFB1—osteoporosis	4.08e-06	1.83e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ESR1—osteoporosis	4.07e-06	1.82e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—TPI1—osteoporosis	4.05e-06	1.81e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—MYC—osteoporosis	3.99e-06	1.78e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TGFB1—osteoporosis	3.98e-06	1.78e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CYP19A1—osteoporosis	3.81e-06	1.71e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ENO1—osteoporosis	3.81e-06	1.7e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—P4HB—osteoporosis	3.8e-06	1.7e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MYC—osteoporosis	3.8e-06	1.7e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IRS1—osteoporosis	3.8e-06	1.7e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TGFB1—osteoporosis	3.79e-06	1.7e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—MYC—osteoporosis	3.77e-06	1.68e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—TGFB1—osteoporosis	3.76e-06	1.68e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PSMA2—osteoporosis	3.75e-06	1.68e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PSMA5—osteoporosis	3.75e-06	1.68e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GAPDH—osteoporosis	3.73e-06	1.67e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—POMC—osteoporosis	3.66e-06	1.64e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—IL6—osteoporosis	3.66e-06	1.64e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—RAP1A—osteoporosis	3.64e-06	1.63e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CYP19A1—osteoporosis	3.59e-06	1.61e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—IL6—osteoporosis	3.59e-06	1.61e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ADCY5—osteoporosis	3.58e-06	1.6e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL6R—osteoporosis	3.57e-06	1.6e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—GPX1—osteoporosis	3.57e-06	1.6e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IGF1—osteoporosis	3.52e-06	1.58e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—IL6—osteoporosis	3.44e-06	1.54e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—IL6—osteoporosis	3.41e-06	1.53e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—IL6—osteoporosis	3.4e-06	1.52e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—IL6—osteoporosis	3.38e-06	1.51e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—IL6—osteoporosis	3.32e-06	1.49e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—MTHFR—osteoporosis	3.29e-06	1.47e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—IL6—osteoporosis	3.15e-06	1.41e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MYC—osteoporosis	3.15e-06	1.41e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—IL6—osteoporosis	3.14e-06	1.41e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TGFB1—osteoporosis	3.14e-06	1.41e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ADCY5—osteoporosis	3.12e-06	1.39e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GPX1—osteoporosis	3.11e-06	1.39e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MYC—osteoporosis	3.09e-06	1.38e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TGFB1—osteoporosis	3.08e-06	1.38e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—IL6—osteoporosis	3.08e-06	1.38e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL6—osteoporosis	3.07e-06	1.37e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP19A1—osteoporosis	3.05e-06	1.36e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—MYC—osteoporosis	3.02e-06	1.35e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—TGFB1—osteoporosis	3.01e-06	1.35e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL6—osteoporosis	3e-06	1.34e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IL6—osteoporosis	3e-06	1.34e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ENO1—osteoporosis	2.94e-06	1.32e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ADCY5—osteoporosis	2.94e-06	1.31e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MYC—osteoporosis	2.93e-06	1.31e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GPX1—osteoporosis	2.93e-06	1.31e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TGFB1—osteoporosis	2.93e-06	1.31e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MYC—osteoporosis	2.93e-06	1.31e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TGFB1—osteoporosis	2.92e-06	1.31e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PSMA5—osteoporosis	2.9e-06	1.3e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PSMA2—osteoporosis	2.9e-06	1.3e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—MTHFR—osteoporosis	2.87e-06	1.28e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IL6—osteoporosis	2.86e-06	1.28e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—IL6—osteoporosis	2.83e-06	1.27e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—MTHFR—osteoporosis	2.7e-06	1.21e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MYC—osteoporosis	2.64e-06	1.18e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—POMC—osteoporosis	2.63e-06	1.18e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TGFB1—osteoporosis	2.63e-06	1.18e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MYC—osteoporosis	2.58e-06	1.16e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TGFB1—osteoporosis	2.58e-06	1.15e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ADCY5—osteoporosis	2.49e-06	1.11e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GPX1—osteoporosis	2.48e-06	1.11e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL6—osteoporosis	2.46e-06	1.1e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL6—osteoporosis	2.37e-06	1.06e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP19A1—osteoporosis	2.35e-06	1.05e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL6—osteoporosis	2.32e-06	1.04e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—POMC—osteoporosis	2.29e-06	1.03e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—MTHFR—osteoporosis	2.29e-06	1.02e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—IL6—osteoporosis	2.27e-06	1.02e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL6—osteoporosis	2.21e-06	9.87e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL6—osteoporosis	2.2e-06	9.84e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—POMC—osteoporosis	2.16e-06	9.67e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MYC—osteoporosis	2.12e-06	9.47e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TGFB1—osteoporosis	2.11e-06	9.44e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL6—osteoporosis	1.98e-06	8.87e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL6—osteoporosis	1.94e-06	8.68e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ADCY5—osteoporosis	1.92e-06	8.59e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GPX1—osteoporosis	1.91e-06	8.56e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—POMC—osteoporosis	1.83e-06	8.19e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—MTHFR—osteoporosis	1.77e-06	7.9e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL6—osteoporosis	1.59e-06	7.12e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—POMC—osteoporosis	1.41e-06	6.32e-06	CbGpPWpGaD
